ESRP1 as a prognostic factor of non-small-cell lung cancer is related to the EMT transcription factor of Twist.
Adult
Aged
Biomarkers, Tumor
/ genetics
Carcinoma, Non-Small-Cell Lung
/ genetics
Epithelial-Mesenchymal Transition
/ genetics
Female
Gene Expression Regulation, Neoplastic
/ genetics
Humans
Lung Neoplasms
/ genetics
Male
Middle Aged
Prognosis
RNA-Binding Proteins
/ genetics
Twist Transcription Factors
/ genetics
EMT
ESRP1
Twist
biomarker
non-small-cell lung cancer
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
10
07
2021
received:
31
05
2021
accepted:
12
07
2021
pubmed:
4
8
2021
medline:
29
1
2022
entrez:
3
8
2021
Statut:
ppublish
Résumé
Non-small-cell lung cancer (NSCLC) is one of the most common fatal cancers in the world. Although the treatment of NSCLC has been significantly improved, there is still an unmet need to identify novel targets for developing therapeutic agents and diagnostic/prognostic markers. The aim of this study is explore the role and underlying mechanism of the epithelial splicing regulatory protein (ESRP1) in the development and progression of NSCLC. A total of 115 participants, 65 cases of NSCLC, 20 cases of precancerous lesions, and 30 cases of benign lung nodules, were included in this study. The expressions of ESRP1 and related transcription factor Twist in enrolled lung tissues were evaluated by histochemistry and immunohistochemistry assay. The survival analysis and related prognosis factors were evaluated by the Kaplan-Meier curve and Cox regression. In addition, the expression of ESRP1 and epithelial-mesenchymal transition (EMT)related transcription factor Twist and EMT markers E-cadherin and N-cadherin were ascertained by immunohistochemical and immunoblotting assay on A549 lung adenocarcinoma cell lines that were exposed to transforming growth factor β1 (TGFβ1). Compared with normal lung tissues, the abundance of ESRP1 protein was significantly increased in precancerous lesions and lung cancer. Correlation analysis demonstrated that ESRP1 was an independent prognostic factor in NSCLC. The expression of ESRP1 and Twist was positively correlated in lung tissues (r = 0.285, p < 0.001). In vitro analysis further showed that TGFβ1 could upregulate the expression of EMT transcription factor Twist while downregulating ESRP1. Our data suggest that the aberrant expression of ESRP1 is an early event in the development of NSCLC. The ESRP1 could serve as a prognostic biomarker for NSCLC, particularly when combined with Twist. The Twist negatively regulated the expression of ESRP1, emphasizing the role of the TGFβ/ESRP1 pathway in the development of NSCLC, which warrants further investigation.
Identifiants
pubmed: 34342121
doi: 10.1111/1759-7714.14088
pmc: PMC8447917
doi:
Substances chimiques
Biomarkers, Tumor
0
ESRP1 protein, human
0
RNA-Binding Proteins
0
Twist Transcription Factors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2449-2457Informations de copyright
© 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
Am J Pathol. 2018 Aug;188(8):1882-1894
pubmed: 29803834
Cancer Res. 2007 Dec 1;67(23):11147-57
pubmed: 18056439
Thorax. 2013 Jun;68(6):551-64
pubmed: 23399908
Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42
pubmed: 16493418
RNA Biol. 2009 Nov-Dec;6(5):546-62
pubmed: 19829082
Cell Res. 2009 Feb;19(2):156-72
pubmed: 19153598
Nat Rev Cancer. 2013 Feb;13(2):97-110
pubmed: 23344542
Cell. 2009 Nov 25;139(5):871-90
pubmed: 19945376
PLoS Genet. 2011 Aug;7(8):e1002218
pubmed: 21876675
J Biol Chem. 2012 Oct 19;287(43):36435-42
pubmed: 22961986
Cell. 2004 Jun 25;117(7):927-39
pubmed: 15210113
Cell Cycle. 2008 Jul 15;7(14):2090-6
pubmed: 18635960
Int J Cancer. 2011 Nov 15;129(10):2310-4
pubmed: 21792896
Thorac Cancer. 2021 Sep;12(18):2449-2457
pubmed: 34342121
Br J Cancer. 2016 Nov 22;115(11):1408-1415
pubmed: 27780193
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
EMBO J. 2012 Jan 4;31(1):110-23
pubmed: 21983900
Semin Cancer Biol. 2012 Oct;22(5-6):417-27
pubmed: 22548723
Lancet. 2015 Mar 14;385(9972):977-1010
pubmed: 25467588
J Clin Invest. 2016 Sep 1;126(9):3219-35
pubmed: 27500490
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Cell. 2016 Jun 30;166(1):21-45
pubmed: 27368099